Maculaser

Maculaser is a company headquartered in Finland. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 2 investors associated with the company.

Maculaser develops a patented temperature-controlled retinal laser therapy that uses personalized, gentle local heating to activate natural cellular defense mechanisms for the treatment and prevention of retinal disorders such as age-related macular degeneration and macular edemas.